Tat-PYC-SMAD7

Tat-PYC-SMAD7 is a recombinant fusion protein consisting of a truncated human Smad7 protein fused with the cell-penetrating HIV-Tat peptide. It is designed for topical application to treat oral mucositis, particularly that induced by intensity modulated radiation therapy. The drug acts by penetrating epithelial cells and modulating local molecular pathways involved in inflammation, cell death, and tissue repair. Mechanistically, Tat-PYC-SMAD7 inhibits TGF-β and NFκB signaling pathways, leading to reduced inflammation (lower IL-1β and TNF-α), decreased DNA damage, reduced neutrophil infiltration, and enhanced DNA repair in affected tissues. Preclinical studies in dogs have shown that topical application of this biologic shortens the duration of severe oral mucositis without detectable systemic absorption[1][2][4].

Other names

Tat-PYC-Smad7Tat-PYC-Smad-7Tat-PYC-Smad 7